BGC vs CNO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BGC has a stable Piotroski F-Score of 6/9, indicating moderate financial health, but the absence of an Altman Z-Score limits distress risk assessment. The stock shows strong revenue and earnings growth, with a high ROE of 14.56%, yet trades at a premium valuation (P/E 27.84 vs sector avg 22.39) despite a low Graham Number of $3.82, suggesting overvaluation on a defensive basis. While analyst consensus is strong_buy, insider selling worth $5.82M and a bearish technical trend signal caution. The fair value estimate is adjusted above the Graham Number due to growth metrics but tempered by leverage and weak technicals.
CNO presents a conflicting profile: while the company demonstrates a strong track record of earnings beats and a stable Piotroski F-Score of 4/9, it is currently trading at a significant premium to its Intrinsic Value ($16.10) and Graham Number ($38.01). The valuation is supported by a low forward P/E of 8.92, but this is offset by a highly bearish technical trend (10/100) and aggressive insider selling. Overall, the strong operational performance is currently decoupled from the deteriorating insider sentiment and technical momentum.
Compare Another Pair
Related Comparisons
BGC vs CNO: Head-to-Head Comparison
This page compares BGC Group, Inc. (BGC) and CNO Financial Group, Inc. (CNO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.